MX2020002762A - Composiciones y métodos para tratar una lesión cerebral. - Google Patents
Composiciones y métodos para tratar una lesión cerebral.Info
- Publication number
- MX2020002762A MX2020002762A MX2020002762A MX2020002762A MX2020002762A MX 2020002762 A MX2020002762 A MX 2020002762A MX 2020002762 A MX2020002762 A MX 2020002762A MX 2020002762 A MX2020002762 A MX 2020002762A MX 2020002762 A MX2020002762 A MX 2020002762A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- treating
- brain injury
- compounds
- Prior art date
Links
- 208000029028 brain injury Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762559113P | 2017-09-15 | 2017-09-15 | |
| US201762584343P | 2017-11-10 | 2017-11-10 | |
| US201862658758P | 2018-04-17 | 2018-04-17 | |
| PCT/US2018/051331 WO2019055913A1 (en) | 2017-09-15 | 2018-09-17 | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002762A true MX2020002762A (es) | 2020-09-17 |
Family
ID=65723435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002762A MX2020002762A (es) | 2017-09-15 | 2018-09-17 | Composiciones y métodos para tratar una lesión cerebral. |
Country Status (13)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011272738B2 (en) | 2010-07-01 | 2015-08-20 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| BR112016022575A2 (pt) | 2014-03-28 | 2017-08-15 | Azevan Pharmaceuticals Inc | Composições e métodos para o tratamento de doenças neurodegenerativas |
| ES2975136T3 (es) * | 2016-03-30 | 2024-07-03 | Sinntaxis AB | Moduladores alost alostéricos negativos de MGLUR5 para uso en el tratamiento de daños cerebrales maduros |
| KR102790657B1 (ko) | 2017-09-15 | 2025-04-02 | 아제반 파마슈티칼스, 인코퍼레이티드 | 뇌 손상을 치료하기 위한 조성물 및 방법 |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| CN115350186A (zh) * | 2022-08-31 | 2022-11-18 | 中国人民解放军军事科学院军事医学研究院 | Sxr246在制备治疗创伤性脑损伤及预后不良药物中的应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4341698A (en) | 1979-06-21 | 1982-07-27 | Richardson-Merrell Inc. | Enkaphalin derivatives |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| JPS6033439B2 (ja) | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | ジペプチドの製造方法 |
| JPS56125361A (en) | 1980-03-07 | 1981-10-01 | Sagami Chem Res Center | Azetidinone compound |
| FR2508035A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
| US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
| US4751299A (en) | 1983-11-18 | 1988-06-14 | Takeda Chemical Industries, Ltd. | Optically active β-lactams and method of their production |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4734498A (en) | 1986-07-10 | 1988-03-29 | Eli Lilly And Company | 3β-succinimidoazetidinones as chiral intermediates |
| US4772694A (en) | 1986-07-24 | 1988-09-20 | Eli Lilly And Company | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| WO1992005784A1 (en) | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
| GB9204001D0 (en) | 1992-02-25 | 1992-04-08 | Jacobs Suchard Ag | Process for producing reduced fat nuts |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| AU4713293A (en) | 1992-07-13 | 1994-01-31 | Merck Sharp & Dohme Limited | Heterocyclic amide derivatives as tachykinin derivatives |
| CA2140640A1 (en) | 1992-08-13 | 1994-03-03 | David C. Horwell | Tachykinin antagonists |
| FR2696178B1 (fr) | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| WO1994026735A1 (en) | 1993-05-06 | 1994-11-24 | Merrell Dow Pharmaceuticals Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5759865A (en) | 1995-05-03 | 1998-06-02 | Eli Lilly And Company | Combinatorial process for synthesizing azetidinone analogs |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| US6204260B1 (en) | 1996-02-23 | 2001-03-20 | Eli Lilly And Company | Non-peptidyl vasopressin V1a antagonists |
| KR20000069431A (ko) | 1996-12-13 | 2000-11-25 | 피터 지. 스트링거 | Ｐｓａ의 효소 활성 억제제 |
| EP0987266A4 (en) * | 1997-03-31 | 2000-07-26 | Wakamoto Pharma Co Ltd | BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS |
| IL133788A0 (en) | 1997-07-30 | 2001-04-30 | American Home Prod | Tricyclic vasopressin agonists |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| BR9812772A (pt) | 1997-10-27 | 2000-10-10 | Reddy Research Foundation | "compostos tricìclicos inéditos e o seu emprego na medicina;processo para a sua preparação e composições farmacêuticas contendo os mesmos" |
| WO2001012171A2 (en) | 1999-08-16 | 2001-02-22 | Revaax Pharmaceuticals, Llc | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| GB0019006D0 (en) | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
| AU2002342045C1 (en) | 2001-10-12 | 2009-07-30 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin Vla antagonists |
| WO2003051314A2 (en) | 2001-12-18 | 2003-06-26 | Medallion Biomedical, Llc | Antibiotic compounds |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| GB0224919D0 (en) | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
| WO2005035492A1 (en) | 2003-10-03 | 2005-04-21 | Serenix Pharmaceuticals, Llc. | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| EP1669776A1 (de) | 2004-12-11 | 2006-06-14 | Leica Geosystems AG | Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät |
| FR2881744B1 (fr) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique |
| CN104922117A (zh) | 2005-03-22 | 2015-09-23 | 阿泽范药品公司 | 用于治疗月经前病症的β-内酰氨基链烷酸 |
| EP1885713A1 (en) | 2005-05-18 | 2008-02-13 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| CA2615813C (en) | 2005-07-19 | 2015-12-15 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
| WO2007109615A2 (en) | 2006-03-21 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS |
| WO2008034032A2 (en) | 2006-09-14 | 2008-03-20 | Azevan Pharmaceuticals, Inc. | Beta-lactam cannabinoid receptor modulators |
| EP2076517A1 (en) | 2006-09-22 | 2009-07-08 | Janssen Pharmaceutica N.V. | Spiro benzazepines as vasopressin antagonists |
| WO2008036755A1 (en) * | 2006-09-22 | 2008-03-27 | Janssen Pharmaceutica N.V. | Spiro benzazepines used as vasopressin antagonists |
| JP5450108B2 (ja) | 2007-03-23 | 2014-03-26 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤としての２−アミノピリジン類似体 |
| FR2927625B1 (fr) | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
| FR2930249B1 (fr) | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
| AU2011272738B2 (en) * | 2010-07-01 | 2015-08-20 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| CN102156420B (zh) | 2010-12-23 | 2012-11-07 | 天津职业技术师范大学 | 加快从计算机下载数据到单片机目标存储器的装置 |
| US20150376198A1 (en) * | 2013-02-18 | 2015-12-31 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| BR112016022575A2 (pt) * | 2014-03-28 | 2017-08-15 | Azevan Pharmaceuticals Inc | Composições e métodos para o tratamento de doenças neurodegenerativas |
| KR102790657B1 (ko) | 2017-09-15 | 2025-04-02 | 아제반 파마슈티칼스, 인코퍼레이티드 | 뇌 손상을 치료하기 위한 조성물 및 방법 |
-
2018
- 2018-09-17 KR KR1020207010875A patent/KR102790657B1/ko active Active
- 2018-09-17 MY MYPI2020001313A patent/MY208313A/en unknown
- 2018-09-17 AU AU2018333051A patent/AU2018333051B2/en active Active
- 2018-09-17 WO PCT/US2018/051331 patent/WO2019055913A1/en not_active Ceased
- 2018-09-17 CN CN201880070936.8A patent/CN111295373B/zh active Active
- 2018-09-17 JP JP2020515077A patent/JP2020534274A/ja active Pending
- 2018-09-17 BR BR112020005107-1A patent/BR112020005107A2/pt unknown
- 2018-09-17 CA CA3075759A patent/CA3075759A1/en active Pending
- 2018-09-17 MX MX2020002762A patent/MX2020002762A/es unknown
- 2018-09-17 US US16/646,744 patent/US11628160B2/en active Active
- 2018-09-17 EP EP18855876.1A patent/EP3681871A4/en active Pending
- 2018-09-17 IL IL273228A patent/IL273228B2/en unknown
-
2020
- 2020-03-24 ZA ZA2020/01880A patent/ZA202001880B/en unknown
-
2023
- 2023-04-17 US US18/135,225 patent/US20240115553A1/en not_active Abandoned
- 2023-09-25 JP JP2023161532A patent/JP7699634B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202001880B (en) | 2022-06-29 |
| IL273228B2 (en) | 2025-04-01 |
| WO2019055913A1 (en) | 2019-03-21 |
| JP2023179559A (ja) | 2023-12-19 |
| CN111295373B (zh) | 2024-12-10 |
| JP7699634B2 (ja) | 2025-06-27 |
| US20200276167A1 (en) | 2020-09-03 |
| CA3075759A1 (en) | 2019-03-21 |
| IL273228A (en) | 2020-04-30 |
| JP2020534274A (ja) | 2020-11-26 |
| IL273228B1 (en) | 2024-12-01 |
| EP3681871A4 (en) | 2021-05-26 |
| CN111295373A (zh) | 2020-06-16 |
| KR20200071075A (ko) | 2020-06-18 |
| EP3681871A1 (en) | 2020-07-22 |
| MY208313A (en) | 2025-04-30 |
| RU2020110038A (ru) | 2021-10-15 |
| AU2018333051A1 (en) | 2020-03-26 |
| US11628160B2 (en) | 2023-04-18 |
| TW201919625A (zh) | 2019-06-01 |
| AU2018333051B2 (en) | 2024-03-21 |
| KR102790657B1 (ko) | 2025-04-02 |
| BR112020005107A2 (pt) | 2020-11-03 |
| US20240115553A1 (en) | 2024-04-11 |
| RU2020110038A3 (cg-RX-API-DMAC10.html) | 2021-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019006160A2 (pt) | composições e métodos para o tratamento das condições oftálmicas | |
| CO2019007829A2 (es) | (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| MX386598B (es) | Compuestos antibacterianos. | |
| BR112016029864A2 (pt) | métodos e dispositivos para tratamento de desordens oculares posteriores. | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| LT3513809T (lt) | Medicininė kompozicija, apimanti tivozanibą | |
| BR112016025997A2 (pt) | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica | |
| MX373703B (es) | Derivados de azepano y metodos para tratar infecciones por hepatitis b. | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2018000778A (es) | Metodos para tratar trastornos mediados por hepcidinas. | |
| MX382904B (es) | Combinaciones de fármacos para tratar mieloma múltiple. | |
| MY208313A (en) | Compositions and methods for treating brain injury | |
| IL271728A (en) | Materials, uses and treatment methods | |
| CO2018007237A2 (es) | Reguladores del cftr y métodos para su uso | |
| MX392383B (es) | Metodos para tratar afecciones oculares. | |
| IL270070B1 (en) | Compounds, compositions and methods of treating or preventing acute lung injury | |
| MX2017007000A (es) | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas. | |
| BR112018009745A8 (pt) | compostos heterocíclicos para o tratamento de doença | |
| IT201700104446A1 (it) | Compositions, uses and methods for treatment of infertility and subfertility | |
| EP3615020A4 (en) | METHODS, AGENTS AND COMPOSITIONS FOR TREATMENT OF ACUTE MYELOIC LEUKEMIA | |
| LT3519050T (lt) | Kompozicijos, skirtos oftalmologinių būklių gydymui | |
| PL3423440T3 (pl) | Pochodna 5-metylo-6-fenylo-4,5-dihydro-2h-pirydazyn-3-onu do leczenia nowotworów mózgu | |
| MX2018004632A (es) | Metodos y composiciones para el tratamiento de una lesion cerebral traumatica. |